Viral Infectivity Assay

Serial dilutions create a range of virus concentrations that can be tested on susceptible cultured cells. Researchers then quantify observable infection outcomes, such as plaques, infected cell foci, or cytopathic effects, and use those measurements to calculate infectious titer. This approach helps relate the amount of virus applied to the number of infection-producing events detected.

Susceptible cells provide the biological context needed for infection and production of new infectious progeny. If virus particles cannot effectively interact with or replicate in the selected cells, the assay may not reflect functional infectivity. In immunology and infection studies, cell susceptibility therefore helps reveal changes in virus-host interactions that genetic detection alone cannot show.

Genetic material indicates that viral sequences are present, but it does not by itself establish that particles can infect cells and generate new infectious progeny. Infectivity measurements add this functional distinction. Comparing infectious titer with particle or genome-related measurements can therefore help identify changes in viral performance that are not explained by particle number alone.

The principal readouts described for this assay are plaques, infected cell foci, and cytopathic effects. Plaques and foci provide visible measures of localized infection, whereas cytopathic effects reflect virus-associated changes in cultured cells. The selected readout supplies the basis for quantifying infection and calculating an infectious titer from the tested virus dilutions.

Researchers can use changes in measured infectivity to characterize whether neutralizing antibodies affect the virus's ability to infect susceptible cells. The assay connects antibody exposure with functional outcomes, such as altered plaques, foci, or cytopathic effects. This makes it possible to assess antibody activity through its effect on infectious virus rather than through detection of viral material alone.

In vaccine research, infectivity measurements help characterize vaccine-induced immunity by showing how functional virus infection changes under the tested conditions. In antiviral studies, the same type of measurement supports evaluation of antiviral efficacy. Because the outcome reflects infection-producing capacity, the assay can connect immune or treatment effects with a biologically relevant change in viral function.